Wu JS, et al. - To assess the role of adjuvant chemotherapy after concurrent chemoradiotherapy (CRT) for nasopharyngeal carcinoma (NPC), experts reported the results of their phase II prospective study where adjuvant chemotherapy was withheld in a subgroup of patients with American Joint Committee on Cancer (AJCC) stage II and III NPC with low risk for metastasis. For selected patients with stage II and III NPC, findings suggested it was safe to withhold adjuvant chemotherapy. With a median follow-up of 107 months, the 5-year overall survival, disease-free survival, and distant metastasis-free survival were 92.4%, 84.4%, and 90.7% for all patients; 94.1%, 85.9%, and 92.9% for patients with stage II NPC; and 90.9%, 83.2%, and 88.9% for patients with stage III NPC, respectively.